Andrew Scharenberg, MD
Andrew M. Scharenberg, MD, is an attending physician at Seattle Children’s Hospital, professor in the Department of Pediatrics, and an adjunct professor in the Department of Immunology at the University of Washington School of Medicine teaching both undergraduates and graduate students. He participates in Seattle Children Hospital’s Immunodeficiency Clinic and the Inpatient Immunology Consult Service. Dr. Scharenberg’s clinical interests are focused on diagnosis and care of patients with inherited diseases of immune function and the implementation of curative molecular therapies for these patients. His efforts in these activities are closely linked with the Scharenberg Laboratory’s translational work on gene editing technology.
Dr. Scharenberg received the American Pediatric Society/Society for Pediatric Research National Young Investigator Award in 2002. He is an active member of the American Society for Clinical Investigation and the American Pediatric Society. He is a member of the Transplantation Biology Consortium Program at Fred Hutchinson Cancer Research Center, and co-directs the Program for Cell and Gene Therapy at Seattle Children’s Research Institute. He was a co-founder of gene editing pioneer Pregenen, acquired by bluebird bio in 2014.